Reata Pharmaceuticals (RETA) IPO Opens Flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) to Ring The Nasdaq Stock Market Closing Bell
May 26, 2016 6:00 AM EDTADVISORY, May 26, 2016 (GLOBE NEWSWIRE) --
What:Reata Pharmaceuticals, Inc. (Nasdaq: RETA), will visit the Nasdaq MarketSite in Times Square in celebration of the companys initial public offering (IPO) on May 26, 2016.
In honor of the occasion, Warren Huff, President and Chief Executive Officer, will ring the Closing Bell.Â
Where:Nasdaq MarketSite 4 Times Square 43rd & Broadway Broadcast Studio
When:Thursday, May 26, 2016 3:45 p.m. to 4:00 p.m. ET Â Â Â
Reata Media Contact:Lee Stern(646)... More
Reata Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
May 25, 2016 11:18 PM EDTIRVING, Texas, May 25, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Reata), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 5,500,000 shares of its Class A common stock at $11.00 per share, before underwriting discounts and commissions. Reata has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its Class A common stock at the initial public offering price. The shares of Class A common stock are expected to begin trading on The NASDAQ Global Market on May 26, 2016, under the ticker symbol RETA.
Reata anticipates the proceeds from the offering (after... More
